In addition, the translational potential of an OATP1B3 inhibitor–based intervention strategy to prevent VIPN is supported by our observation that nilotinib does not antagonize the cytotoxic effects of vincristine against preclinical models of leukemia (Figure 4, E and F). This evidence concerns the gene SLCO1B3 and leukemia.